NEWS

ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology that will leverage ANGLE’s existing DNA damage response (DDR) assay for the detection of micronuclei in circulating tumour cells (CTCs) as a measure of DDR.

Under the terms of the agreement, ANGLE will ‘develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DDR’, according to the company’s press release.

The development of these assays will take place at ANGLE’s laboratories in Guildford, UK, and follows its development and launch of two sensitive and specific DDR assays during 2023.

Karen Miller, ANGLE’s chief scientific officer, stated: “We are delighted that our expertise in CTC assay development continues to make great strides. With the increasing investigation of DDR/PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers.”

Andrew Newland, ANGLE’s chief executive officer, commented: “This is ANGLE’s second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of ANGLE’s Parsortix system. ANGLE is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity.”